IMMU-110

drug immunoconjugate composed of doxorubicin conjugated to the humanized anti-CD74 monoclonal antibody, hLL1, at a doxorubicin/monoclonal antibody ratio of approximately 8:1 (mol/mol); the excellent safety and efficacy profile of IMMU-110 supports clinical testing of this immunoconjugate in the treatment of CD74-positive B-cell malignancies

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cardillo, Thomas M: 1 article (07/2005)
2.	Goldenberg, David M: 1 article (07/2005)
3.	Govindan, Serengulam V: 1 article (07/2005)
4.	Griffiths, Gary L: 1 article (07/2005)
5.	Hansen, Hans J: 1 article (07/2005)
6.	Horak, Ivan D: 1 article (07/2005)
7.	Pickett, Jennifer: 1 article (07/2005)
8.	Qu, Zhengxing: 1 article (07/2005)
9.	Sapra, Puja: 1 article (07/2005)
10.	Stein, Rhona: 1 article (07/2005)

Related Diseases

1.	Neoplasms (Cancer) 07/15/2005 - "Pharmacokinetics and biodistribution of radiolabeled IMMU-110 were examined in tumor-free BALB/c mice, and the therapeutic effectiveness was evaluated in severe combined immunodeficient mice bearing MC/CAR cells. " 07/15/2005 - "The excellent safety and efficacy profile of IMMU-110 supports clinical testing of this immunoconjugate in the treatment of CD74-positive B-cell malignancies."
2.	Multiple Myeloma 07/15/2005 - "Here, we describe safety evaluations of IMMU-110 in mice and monkeys as well as efficacy studies in a xenograft model of the human multiple myeloma cell line, MC/CAR. " 07/15/2005 - "Treatment with a single dose of IMMU-110 as low as 50 microg antibody/mouse (or 1.4 microg doxorubicin/mouse), 5 days postinjection of the multiple myeloma cells, resulted in cure of most mice. " 07/15/2005 - "Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys."

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)
2.	Doxorubicin (Adriamycin)